Income Taxes	3 Months Ended
Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 16. INCOME TAXES During the three months ended March 31, 2016, the Company recognized an income tax benefit of $118.7 million on $207.5 million of loss from continuing operations before income tax, compared to $166.9 million of tax benefit on $16.4 million of loss from continuing operations before income tax during the comparable 2015 period. The tax benefit for the current period is primarily related to the overall geographical mix of pretax earnings as well as the discrete tax benefit associated with the impairment associated with the U.S. Generic Pharmaceutical business. The tax benefit for the comparable 2015 period was primarily related to benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business that was held for sale in such period.

Income Taxes

3 Months Ended

Mar. 31, 2016

NOTE 16. INCOME TAXES

During the three months ended March 31, 2016, the Company recognized an income tax benefit of $118.7 million on $207.5 million of loss from continuing operations before income tax, compared to $166.9 million of tax benefit on $16.4 million of loss from continuing operations before income tax during the comparable 2015 period. The tax benefit for the current period is primarily related to the overall geographical mix of pretax earnings as well as the discrete tax benefit associated with the impairment associated with the U.S. Generic Pharmaceutical business. The tax benefit for the comparable 2015 period was primarily related to benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business that was held for sale in such period.